Akebia Therapeutics (AKBA) Competitors $2.81 -0.11 (-3.77%) Closing price 04:00 PM EasternExtended Trading$2.82 +0.02 (+0.53%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKBA vs. IMVT, HCM, AMRX, OGN, MIRM, APLS, DNLI, VCEL, NAMS, and AAPGShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Immunovant (IMVT), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Denali Therapeutics (DNLI), Vericel (VCEL), NewAmsterdam Pharma (NAMS), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Immunovant HUTCHMED Amneal Pharmaceuticals Organon & Co. Mirum Pharmaceuticals Apellis Pharmaceuticals Denali Therapeutics Vericel NewAmsterdam Pharma Ascentage Pharma Group International Akebia Therapeutics (NASDAQ:AKBA) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership. Do analysts rate AKBA or IMVT? Akebia Therapeutics presently has a consensus target price of $6.63, suggesting a potential upside of 135.77%. Immunovant has a consensus target price of $38.33, suggesting a potential upside of 166.02%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Immunovant 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Does the media prefer AKBA or IMVT? In the previous week, Immunovant had 9 more articles in the media than Akebia Therapeutics. MarketBeat recorded 12 mentions for Immunovant and 3 mentions for Akebia Therapeutics. Immunovant's average media sentiment score of 1.48 beat Akebia Therapeutics' score of 1.46 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, AKBA or IMVT? Akebia Therapeutics has higher revenue and earnings than Immunovant. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$184.91M3.99-$51.92M-$0.21-13.38ImmunovantN/AN/A-$259.34M-$2.62-5.50 Is AKBA or IMVT more profitable? Immunovant has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -27.07%. Akebia Therapeutics' return on equity of 0.00% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-27.07% N/A -20.57% Immunovant N/A -77.94%-69.82% Which has more volatility and risk, AKBA or IMVT? Akebia Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Do insiders and institutionals hold more shares of AKBA or IMVT? 33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by company insiders. Comparatively, 5.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community favor AKBA or IMVT? Akebia Therapeutics received 290 more outperform votes than Immunovant when rated by MarketBeat users. However, 77.65% of users gave Immunovant an outperform vote while only 63.08% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformAkebia TherapeuticsOutperform Votes42263.08% Underperform Votes24736.92% ImmunovantOutperform Votes13277.65% Underperform Votes3822.35% SummaryImmunovant beats Akebia Therapeutics on 9 of the 17 factors compared between the two stocks. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$738.01M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-12.228.9226.8419.71Price / Sales3.99250.95391.39116.98Price / CashN/A65.8538.2534.62Price / Book-17.566.466.794.50Net Income-$51.92M$143.98M$3.23B$248.18M7 Day Performance14.69%3.04%4.07%1.14%1 Month Performance35.75%7.44%12.52%15.20%1 Year Performance148.67%-2.46%16.83%6.56% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics4.225 of 5 stars$2.81-3.8%$6.63+135.8%+153.9%$738.01M$184.91M-12.22430IMVTImmunovant2.7146 of 5 stars$14.55+3.8%$38.33+163.5%-51.4%$2.47BN/A-5.55120Positive NewsHCMHUTCHMED2.2843 of 5 stars$13.92-2.0%$19.00+36.5%-33.9%$2.43B$630.20M0.001,760Positive NewsGap DownAMRXAmneal Pharmaceuticals3.2515 of 5 stars$7.60+2.6%$11.50+51.3%+10.3%$2.36B$2.83B-11.187,600OGNOrganon & Co.4.7569 of 5 stars$8.69-0.2%$18.00+107.1%-59.8%$2.26B$6.29B2.6110,000High Trading VolumeMIRMMirum Pharmaceuticals4.094 of 5 stars$45.57+2.9%$59.00+29.5%+79.2%$2.25B$379.25M-22.56140News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.1715 of 5 stars$17.52+1.3%$41.37+136.1%-57.2%$2.20B$781.37M-8.63770Gap UpDNLIDenali Therapeutics4.4205 of 5 stars$14.80+3.0%$33.79+128.3%-29.0%$2.15B$330.53M-5.36430Analyst ForecastVCELVericel2.5621 of 5 stars$42.65+2.2%$60.86+42.7%-14.9%$2.14B$238.54M710.95300Positive NewsNAMSNewAmsterdam Pharma2.5174 of 5 stars$19.22+4.6%$43.00+123.7%-2.5%$2.11B$45.56M-10.224Gap UpAAPGAscentage Pharma Group InternationalN/A$24.20-0.5%N/AN/A$2.11B$980.65M0.00600Positive NewsGap Up Related Companies and Tools Related Companies IMVT Alternatives HCM Alternatives AMRX Alternatives OGN Alternatives MIRM Alternatives APLS Alternatives DNLI Alternatives VCEL Alternatives NAMS Alternatives AAPG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKBA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKBA Stock Free AKBA Stock Alerts